The potentiation effect of Bawang Dayak (Sisyrinchium palmifolium L.) extract on T47D cell growth inhibition after 5-fluorouracil treatment

Authors

  • Azizah Yuniarti Faculty of Pharmacy, University of Muhammadiyah Purwokerto
  • Elza Sundhani Faculty of Pharmacy, University of Muhammadiyah Purwokerto
  • Nunuk Aries Nurulita Faculty of Pharmacy, University of Muhammadiyah Purwokerto

DOI:

https://doi.org/10.12928/pharmaciana.v8i2.9480

Keywords:

Bawang dayak (Sisyrinchium palmifolium L.), 5-fluorouracil, T47D, co-chemotherapy, apoptosis, cell cycle

Abstract

5-Fluorouracil (5-FU) is chemotherapy agents that used in breast cancer treatment that has toxic effects such as myelotoxicity. its effectiveness relatively low. Bawang Dayak has been widely empirically used as a breast cancer treatment. This study's aims were to determine the sensitivity of 5-FU against T47D cells, as single and its combination with EBD, to determine apoptotic induction, and the inhibitory effect of T47D cell cycle. The cytotoxic assay was using the MTT method with the concetration of 5-FU (0-600μg / mL) and EBD (0-250μg / mL). Apoptotic induction analysis were determined by PI/annexin V. Both of apoptotic and cell cycle analysis was performed by flowcytometry. The results of the 5-FU and EBD cytotoxic test on T47D cells obtained IC50 274μg/mL and 75μg/mL, respectively. The combination of 5-FU and EBD has a mild to strong synergistic effect (CI 0.829 and 0.779). its ombined treatment induced apoptosis in T47D cells by 21.33%. Combination of these combinations caused cell accumulation in G0-G1 phase of 57.11%, greater than control (41.20%). Provision of 5-FU and EBD combination treatments causes disturbance and damage to cells that cause cell cycle arrest in the G0-G1 phase and can not proceed to the next phase. The combination of 5-fluorouracil and EBD has a synergistic effect as breast cancer co-chemotherapy is able to induce apoptosis against T47D cells by triggering cell accumulation in G0-G1 phase. The extract of Bawang Dayak has a high potential to be developed as co-chemotherapy in breast cancer.

References

DepKes RI. 2000. Parameter Standar Umum Ekstrak Tumbuhan Obat. Jakarta: Departemen Kesehatan Republik Indonesia.

Galingging, R. Y. (2009). Bawang Dayak (Eleutherine palmifolia) Sebagai Tanaman Obat Multifungsi. Warta Penelitian dan Pengemangan. 15(3). 2-4.

Hidayah, A. S., Kiki M., Leni P. (2015). Uji Aktivitas Antioksidan Umbi Bawang Dayak (Eleutherine bulbosa Merr.). ISSN 2460-6472.

Longley, D.B. dan Johnston P.G. (2007). 5-Fluorouracil Molecular Mechanism of Cell Death in Srivastava R., Apoptosis, Cell Signaling, and human Disease. Humana Press.

Meyerhardt, J.A. and Mayer R.J. (2005). Systemic Teraphy for Colorectal Cancer. N. Engl. J. Med. 352(5). 476-487.

National Comprehensive Cancer Network. (2014). Stage IV Breast Cancer. NCCN Guidelines for Patient.

Sudarmawan, I. H., 2009,Pengaruh Pemberian Fraksi Etanolik dan Petroleum Eter Ekstrak Umbi Bawang Dayak (Eleutherine palmifolia (L.) Merr.) Terhadap Ekspresi p53 Mutan Galur Sel Kanker Payudara T47D [Skrpsi], Surakarta: Universitas Sebelas Maret.

Yusni, M. A., 2008, Perbedaan Pengaruh Pemberian Fraksi Etanolik Bawang Dayak (Eleutherine palmifolia (L.) Merr.) dengan 5-Fluorouracil Terhadap Penghambatan Pertumbuhan Galur Sel Karsinoma Kolon HT29 dan Ekspresi p53 Mutan [Tugas Akhir], Surakarta, Fakultas Kedokteran, Universitas Sebelas Maret/ RSUD Dr. Moewardi Surakarta.

Downloads

Published

2018-11-24

Issue

Vol. 8 No. 2 (2018): Pharmaciana

Section

Analytical Pharmacy and Medicinal Chemistry

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.